



**ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT247 IN DIABETES CARE**

***AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control***

**Cambridge, UK**, 16 December 2020: Arecor Limited (*"Arecor" or "the Company"*), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that *Diabetes Care* has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate.

The manuscript titled 'Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double blind, Crossover Study in Men with Type 1 Diabetes' is [available online](#) from today.

In the Phase I clinical study, AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with both NovoRapid® and Fiasp®.

AT247, a novel formulation of insulin, aims to accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels. AT247 has the potential to significantly improve post prandial glucose control so avoiding episodes of both hypo and hyperglycemia.

**Dr Eva Svehlikova, first author of the study, said:** "Publication of these data in a peer-reviewed journal supports the representation of AT247 as a promising candidate in the pursuit for next generation ultra-rapid acting insulin designed to improve postprandial glycemic control and flexibility of dosing. This early evidence suggests that AT247 may also facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes."

**Sarah Howell, Chief Executive Officer of Arecor, said:** "Publication of the first AT247 clinical trial marks an important step in our goal to develop a proprietary portfolio of even faster acting insulins targeted at improving treatment and healthcare outcomes for people living with diabetes. With AT247's favourable profile over current treatments, we believe that our products have the potential to advance the diabetic treatment landscape."

The next step on the accelerated development pathway for AT247 will be to further explore the benefits of AT247 in the clinical setting in 2021.

**-ENDS-**



**For more information, please contact:**

**Arecor Limited**

[www.arecor.com](http://www.arecor.com)

Dr Sarah Howell, Chief Executive Officer

Tel: +44 (0) 1223 426060

Email: [info@arecor.com](mailto:info@arecor.com)

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: [info@arecor.com](mailto:info@arecor.com)

**Mo PR Advisory**

[www.mopr Advisory.com](http://www.mopr Advisory.com)

Mo Noonan

Mob: +44 (0) 7876 444977

Email: [mo@mopr Advisory.com](mailto:mo@mopr Advisory.com)

**Notes to Editors**

**About Arecor**

Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

For further details please see our website, [www.arecor.com](http://www.arecor.com)

**About Diabetes Care**

*Diabetes Care* is a journal for the health care practitioner that is intended to increase knowledge, stimulate research, and promote better management of people with diabetes.

For further details please see the website, <https://care.diabetesjournals.org/>